10.1056/NEJMoa066224 62 KanoskiS
doi: 10.3389/fcdhc.2025.1590530 Received 09 March 2025 Accepted 18 June 2025 Published 10 July 2025 Volume 6 - 2025 Edited by Angelo Maria Patti, University of Palermo, Italy Reviewed by Anapaula Sommer Vinagre, Federal University of Rio Grande do Sul, Brazil Jun Eguchi, Okayama University, Japan Updates Copyright 2025 Hammad, Zafar, Ullah, Faisal, Iftikhar, Waheed, Muzaffar, Ahmed, Ashraf, Zahid, Akhtar and Mahmmoud Fadelallah Eljack
More serious potential risks include (not an exhaustive list): Pancreatitis
The 28.7% weight loss and 82% liver fat reduction could justify this designation, particularly for MASLD, which currently has limited treatment options
CV-anchored protocols will drive the bigger wave
Tirzepatide for managing overweight and obesity (TA1026) NICE